FDA Approves Tau-Imaging Agent for Alzheimer's

The brain imaging agent MK-6240, marketed as TAUKLARIFY, lets clinicians and researchers visualize buildup of tau, a protein closely tied to Alzheimer's disease.

Updated on Nov. 20, 2026 in Alzheimer’s

Isometric editorial illustration of a plain glass vial with glowing amber liquid in a lead-grey cradle, set before a soft brain-shaped silhouette.
The FDA approved MK-6240, marketed as TAUKLARIFY, a brain imaging agent that lets clinicians and researchers visualize tau protein buildup linked to Alzheimer's disease. AI Illustration. Upload story photo >

Live Poll

Would you feel more confident in a doctor using new brain scans to diagnose Alzheimer's?

The FDA has approved MK-6240, a brain imaging agent marketed as TAUKLARIFY, that allows clinicians and researchers to visualize tau buildup in the brain. Research from the University of Wisconsin provided critical evidence supporting the approval.

Why it matters

Alzheimer's disease could previously be diagnosed only when an autopsy revealed two abnormal proteins, beta amyloid and tau. Visualizing tau in living patients may help researchers determine which patients will benefit most from drugs targeting tau, which are currently in development.

A 2020 study in the journal Brain followed 167 volunteers using MK-6240 and linked rising tau and beta amyloid levels to declining brain capabilities. The extraction does not report comparator figures or how the agent will perform in routine clinical use.

The players

TAUKLARIFY (MK-6240)

A brain imaging agent that allows clinicians and researchers to visualize tau buildup in the brain, the protein closely associated with Alzheimer's disease.

The details

MK-6240 can be manufactured on demand, and a partnership across teams at the university enabled the studies supporting the agent's approval. Few institutions have the expertise and infrastructure to produce tau tracers on a routine basis, and researchers are using tau PET imaging in clinical trials to determine who will benefit most from treatment.

Timeline

  1. About 20 years ago, the first PET tracer for beta amyloid plaque in living patients was developed.

  2. About a decade later, a tracer for tau tangles was developed.

  3. In 2020, a Brain journal study of 167 volunteers using MK-6240 was published.

  4. On November 20, 2026, the FDA approval of TAUKLARIFY (MK-6240) was reported.

Diagnostic Progression

Approval of TAUKLARIFY extends the sequence begun by the beta amyloid PET tracer about 20 years ago, which made living-patient imaging possible, to tau, the second protein long visible only at autopsy. Tau imaging follows a roughly decade-long gap after the amyloid tracer and arrives as tau-targeting drugs remain in development.

Clinicians may be able to use tau imaging in memory clinics once MK-6240 is commercially available, which could help identify patients who may benefit from future tau-targeting treatments. UW Health is establishing a clinical tau PET program in preparation for that availability.

The takeaway

Tau imaging gives clinicians a way to see one of the two proteins long diagnosable only at autopsy, which may help match patients to future tau-targeting therapies.

Further reading

Explore more on Alzheimer’s research and diagnostic advances.

Source note: This article includes information reported by WXOW.

Live Poll

Would you feel more confident in a doctor using new brain scans to diagnose Alzheimer's?